Shasqi
Pioneering Click Chemistry in Humans to change cancer outcomes
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two 'click', a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.
Latest News
Active Founders
Jose M. Mejia Oneto, Founder/CEO
José M Mejía Oneto is a physician scientist with training in Organic Chemistry at Emory and Orthopedics at UC Davis. During his clinical training, Jose recognized the need for a better way to get drugs to the right location in the body. Joined the YC program in 2015 with Tambo and in 2018 its spinoff Shasqi, focussing on pioneering click chemistry in humans for better cancer drugs. Shasqi has raised a more than $60M in funding, with its lead asset in Phase 2 and a growing pipeline of drugs.
